

1 **Supplementary Table 1: Pharmacokinetic parameters of the study drugs when administered in either a three drug (IDA), a four drug combination**
 2 **(IDA+AZI) or AZI alone.**

Parameter	ALB		ALB-SOX		ALB-SON		DEC		IVM		AZI	
	IDA	IDA+AZI	IDA	IDA+AZI	IDA	IDA+AZI	IDA	IDA+AZI	IDA	IDA+AZI	AZI	IDA+AZI
C _{max} (ng/mL)	40.3 (7.1-140.7)	40.5 (6.7-96.8)	391.6 (177.4-1179.9)	443.6 (190.6-562)	33.4 (10.6-87.4)	25.9 (10.3-85)	1368.9 (1113.6-2836)	1539.1 (1306.8-2779.3)	96.6 (58.3-155)	83.6 (41.4-143.6)	1190.6 (538.4-3208.7)	1648.8 (508.3-3300.4)
T _{max} (hr)	2.5 (2-6)	3 (1-6)	5 (3-8)	6 (3-12)	6 (3-8)	7 (3-12)	3 (1-6)	4 (1-8)	6 (3-12)	6 (3-12)	3.5 (2-8)	4 (2-6)
Half-life (t _{1/2})	5.5 (2.1-18.6)	4.6 (2.4-13.6)	7.3 (4.4-19.7)	8.1 (4.2-16.3)	9.9 (5.5-20.6)	8.9 (5-19.9)	10.7 (9-20)	9.9 (7.9-13.4)	24.3 (19.7-38.6)	33.1 (22.1-45.4)	32.1 (24.5-49.4)	29.9 (23.7-37.7)
AUC _{0-t} (ng*hr/mL)	161.1 (19.8-996.5)	172.3 (36.8-847.4)	5484 (1905.9-19251.2)	5902.2 (3331.3-12334.1)	527.1 (135.7-1902.1)	357.7 (177.8-2187.7)	22967.6 (12874.4-44154.5)	21227.6 (13775.4-32873.6)	1856.1 (961.2-3367.1)	1576.1 (731.7-2445.2)	11332.8 (8168.7-19535.6)	14532 (5771-22480)
AUC _{0-∞} (ng*hr/mL)	162.8 (20.1-998)	175.1 (38.9-866.7)	5487.8 (1907.1-19259.3)	5921.6 (3339.3-13106.7)	551.2 (143.7-1904.1)	368.8 (180.4-2190.8)	23299.3 (12918.7-48157.4)	21397.3 (13857.4-33166.8)	2178.9 (1176.6-4328.3)	2019.9 (925.3-3060.3)	13950.2 (9936-22968)	17298.6 (6870.9-27003)
V _{z/F} (L)	27243.9 (3125.6-120701.2)	17662.9 (6939.5-47639.4)	788.5 (188.3-2821.9)	783.4 (595.2-1365.4)	10501.2 (2157.4-63055.1)	12951.8 (7332.4-32337.9)	127.2 (85.7-179.5)	136.6 (76.5-228.3)	213.9 (117.5-360.5)	332.6 (148.5-748.3)	5484.2 (3995.9-10194.1)	5504.3 (2792.5-10986.6)
CL/F (L/hr)	2596.1 (400.8-19903.1)	2322.1 (461.6-10287.5)	73.0 (20.8-209.7)	68.2 (30.5-119.8)	734.2 (210.1-2784.3)	1084.8 (457.7-2217.7)	7.7 (4.2-13.8)	9.2 (5.4-17.6)	5.6 (3.2-11.2)	6.0 (4.7-13)	129.5 (76.5-176.1)	101.2 (74.1-254.7)
C _{max} adjusted to dose (ng/mL)	20.6 (4-90)	26.3 (4.3-72.6)	222.3 (99.3-648.9)	278.7 (99.1-453.4)	17.5 (7.4-48.1)	15.6 (5.4-43.4)	1420.8 (1026.3-2674.4)	1542.9 (1232.3-2733.8)	96.7 (59.6-144.7)	78.9 (43.9-141.7)	1312.5 (529.8-3465.4)	1905.9 (540.3-3663.4)
AUC _{0-t} adjusted to Dose (ng*hr/mL)	82.2 (11.1-548)	123.2 (23.6-635.5)	3103.7 (1067.3-10588.1)	4712.8 (1732.3-9250.6)	310.9 (76-1046.1)	247 (98.8-1115.7)	22750.8 (12140.9-44891.8)	23147.9 (14073-34875.7)	1746 (1067.9-3068.1)	1567.2 (682.9-2499.5)	12511 (8292.5-24907.8)	14778 (6133.7-25289.9)
AUC _{0-∞} adjusted to dose (ng*hr/mL)	83.2 (11.3-548.9)	125.1 (24.9-650)	3151.3 (1068-10592.6)	4731.3(1736.4-9830)	312.9 (80.4-1047.3)	247.7 (105.7-1117.3)	23079.6 (12182.7-48961.6)	23333.6 (14156.9-35186.8)	2047.5 (1268.1-3866.6)	1962.8 (863.6-3128.3)	16706.8 (10219.9-29284.3)	17208 (7302.8-30378.3)

3

4 Data presented are the median values and ranges for each pharmacokinetic parameter.

5 Data are median (range). T_{1/2} terminal half-life, T_{max} time of maximum plasma concentration, C_{max} maximum plasma concentration, AUC area under the concentration-time curve, Vz/F apparent
 6 volume of distribution, CL/F apparent clearance.

7 ALB, Albendazole; ALB-SOX, albendazole sulfoxide; ALB-SON, albendazole sulfone, DEC, diethylcarbamazine, IVM, ivermectin, AZI, azithromycin.
8 IDA, three drug combination (DEC 6mg/kg+ IVM 200ug/kg + ALB 400mg); IDA+AZI, four drug combination (IVM 200µg/kg + DEC 6mg/kg+ ALB 400mg +AZI 30mg/kg); or AZI (AZI alone 30mg/kg).

9

10